Seventeen patients with acute promyelocytic leukemia (APL) were treated with high doses of Daunorubicin (DNR). Fourteen achieved complete remission (CR) but six relapsed after 9 to 46 months. Five of these six patients were treated again with DNR (2 mg/Kg/day for five days) and achieved a second complete and long-lasting remission. The sixth patient, who received Amsacrine, Vincristine, Cytarabine, achieved only a partial remission and subsequently died 6 months from the onset of relapse. None of the patients treated with DNR showed any signs of irreversible cardiotoxicity due to the drug. The five-year survival rate for all 17 patients was 62.5 percent. The results we obtained confirm that DNR is of extreme benefit in the treatment of APL in relapse and that there is no development of resistance to the drug.
|Number of pages||5|
|Publication status||Published - 1988|
ASJC Scopus subject areas